Reading view
Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
Ann Med. 2026 Dec;58(1):2607229. doi: 10.1080/07853890.2025.2607229. Epub 2025 Dec 26.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remaining the predominant etiological factors. Chronic viral infection not only drives carcinogenesis but also reshapes the hepatic immune microenvironment, profoundly influencing the efficacy and safety of immunotherapy.
RECENT ADVANCES: Immune checkpoint inhibitors (ICIs) have revolutionized systemic therapy for advanced HCC, with agents targeting PD-1/PD-L1 demonstrating clinical benefit. Combination strategies - such as ICIs with anti-angiogenic therapies, multikinase inhibitors, or locoregional treatments - have shown synergistic efficacy and are now standard of care in certain settings. For virus-related HCC, antiviral therapy improves immune responsiveness and reduces risks such as HBV reactivation, underscoring the need for integrated management.
FUTURE PERSPECTIVES: Emerging therapeutic approaches include next-generation immune checkpoints (e.g. TIM-3, LAG-3, TIGIT), bispecific antibodies, cellular therapies (CAR-T, TCR-T, TILs), and tumor vaccines targeting viral or tumor-associated antigens. Advances in biomarker discovery, including circulating tumor DNA, immune signatures, and microbiome modulation, are expected to guide personalized treatment. Integration of multi-omics and clinical data will further refine patient selection and optimize treatment sequencing.
CONCLUSION: Immunotherapy offers new hope for patients with virus-related HCC, but challenges remain in response heterogeneity, resistance, and toxicity. Individualized strategies that combine immunotherapy with effective antiviral management and biomarker-|guided patient selection are essential. Continued translational and clinical research into virus-immune-tumor interactions will enable safer, more effective, and more durable treatment outcomes, ultimately transforming HCC into a more manageable disease.
PMID:41454610 | PMC:PMC12777805 | DOI:10.1080/07853890.2025.2607229
ValuePilot: A Two-Phase Framework for Value-Driven Decision-Making
Why Text Prevails: Vision May Undermine Multimodal Medical Decision Making
Development, advancement, and clinical integration of artificial intelligence technology in gastric cancer
Chin Med J (Engl). 2025 Nov 28;138(24):3332-50. doi: 10.1097/CM9.0000000000003922. Online ahead of print.
ABSTRACT
Personalized medicine for gastric cancer continues to face numerous challenges, primarily due to the complexity of clinical decision making and the difficulty of integrating multimodal data. Artificial intelligence (AI), with its powerful capabilities in feature learning and pattern recognition, is emerging as a key technology to overcome these barriers. It provides critical support in areas such as early screening, histological subtyping, prediction of treatment response, and prognostic risk stratification. This review examines the application of AI in diagnosing and treating gastric cancer, with particular attention to the current mainstream AI methodologies, including feature engineering and deep learning and the rapidly evolving pretrained foundation models and multimodal large models. With the integration of medical images, digital pathology, multiomics data, and structured clinical information, AI systems are increasingly effective at capturing tumor heterogeneity and supporting complex clinical decisions in real time. On the one hand, task-specific models have demonstrated excellent performance in subtyping, staging, and prognosis assessment. On the other hand, the rise of foundation models and general-purpose large models is redefining the limits of AI in cross-task transfer, complex reasoning, and human-machine interaction. These technologies hold promise in addressing key obstacles such as data scarcity, modality heterogeneity, and fragmented clinical workflows, offering a feasible path toward a unified and efficient AI-driven diagnostic and therapeutic system for gastric cancer. As technological maturity progresses alongside the development of robust safety and ethical frameworks, AI is expected to evolve from a static auxiliary interpretation tool into an intelligent decision-making platform capable of semantic understanding, dynamic feedback, and multidisciplinary collaboration-therefore playing a pivotal role across the full spectrum of precision medicine in gastric cancer.
PMID:41400327 | PMC:PMC12721780 | DOI:10.1097/CM9.0000000000003922